Related Experiment Videos
Insights
Calcium channel blockers (CCBs) show unproven efficacy for ischemic heart disease prophylaxis. Long-acting CCBs are recommended for hypertension, pending further safety trials.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Current evidence on calcium channel blockers (CCBs) provides clear messages for prescribers.
- Short-acting dihydropyridine CCBs lack proven prophylactic efficacy in ischemic heart disease.
Discussion:
- CCB use in post-myocardial infarction patients with impaired left ventricular function is linked to unchanged or increased mortality.
- Hypertension management should prioritize established first-line agents like beta-blockers, diuretics, and specific long-acting CCBs (nifedipine GITS, nitrendipine).
Key Insights:
- Short-acting dihydropyridine CCBs are not recommended for preventing ischemic heart disease.
- Long-acting dihydropyridine CCBs (nifedipine GITS, nitrendipine) are suitable for hypertension treatment.
- CCBs may increase mortality in specific post-infarct patient groups.
Outlook:
- The definitive safety profile of CCBs awaits results from ongoing prospective, randomized, placebo-controlled clinical drug trials.
- Future trial outcomes, expected after the year 2000, will inform the final consensus on CCB safety.
Abstract:
What, finally can we conclude from the work to date regarding the use of CCB's? The large clinical trials here give a number of clear messages to the prescriber. Short-acting dihydropyridine CCB's are unproven as prophylactic agents in ischaemic heart disease. In patients with poor left ventricular function post-infarct, CCB's are associated with an unchanged or increased mortality. Use of medications in the treatment of hypertension should be with proven first-line therapeutic agents; beta-blockers, diuretics; and the long-acting dihydropyridine CCB's nifedipine GITS and nitrendipine. The final argument in the discussion over the safety or otherwise of calcium channel blockers will rest in the completion in the future of a number of prospective, randomised, place-controlled clinical drug trials. These trials are currently ongoing, and their results may not be available until after the year 2000.